TP53 and diffuse large B-cell lymphoma: TP53 mutations in DLBCL has been found in 20–30% of DLBCL patients31, 32 and is often associated with treatment resistance, especially mutations in the TP53 DNA‐binding domains that cover exons 5–9.33, 34, 35